{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:53:58Z","timestamp":1792526038756,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012785","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000}}],"reference-count":106,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012785.pub2","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T10:28:56Z","timestamp":1556706536000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Prostacyclin for pulmonary arterial hypertension"],"prefix":"10.1002","volume":"2019","author":[{"given":"Hayley","family":"Barnes","sequence":"first","affiliation":[{"name":"The Alfred Hospital; Department of Respiratory Medicine; Commercial Rd Melbourne Australia 3004"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Yeoh","sequence":"additional","affiliation":[{"name":"The Alfred Hospital; Department of Respiratory Medicine; Commercial Rd Melbourne Australia 3004"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Fothergill","sequence":"additional","affiliation":[{"name":"The Alfred Hospital; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Burns","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay; H\u00f4pital Bic\u00eatre, Assistance Publique H\u00f4pitaux de Paris, Inserm U999, Univ. Paris-Sud; Le Kremlin-Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Williams","sequence":"additional","affiliation":[{"name":"The Alfred Hospital; Department of Respiratory Medicine; Commercial Rd Melbourne Australia 3004"},{"name":"Monash University; Department of Medicine; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD012785.pub2-BIB0001|cit1","first-page":"41","article-title":"Positive outcome of the Aerosolized Iloprost Randomized study in primary and non-primary pulmonary hypertension (AIR study)","volume":"9","author":"Ghofrani","year":"2002","journal-title":"Journal fur Anasthesie und Intensivbehandlung"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD012785.pub2-BIB0002|cit2","first-page":"A411","article-title":"Positive outcome of the aerosolized iloprost randomised trial for treatment of severe pulmonary hypertension (AIR study)","volume":"165","author":"Olschewski","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012785.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012785.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Galie","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD012785.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue in patients with pulmonary arterial hypertension: a randomised, double-blind, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012785.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Barst RJ Rubin LJ Long WA McGoon MD Rich S Badesch DB A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension New England Journal of Medicine 1996 296 301","DOI":"10.1056\/NEJM199602013340504"},{"issue":"6","key":"10.1002\/14651858.CD012785.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/01.CIR.95.6.1479","article-title":"Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group","volume":"95","author":"Hinderliter","year":"1997","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD012785.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0010|cit10","first-page":"A5906","article-title":"Combination therapy for pulmonary arterial hypertension with oral treprostinil: long-term follow up [Abstract]","volume":"183","author":"Ruggiero","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Tapson V Jing ZC Xu K Pan L Feldman J Kiely D Freedom-C2: efficacy and safety of oral treprostinil diethanolamine in combination with an era and\/or a PDE5 inhibitor in patients with pulmonary arterial hypertension American Journal of Respiratory and Critical Care Medicine 2012 A2493","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2493"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD012785.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1044A","DOI":"10.1378\/chest.1212098","article-title":"FREEDOM-M: efficacy and safety of oral treprostinil diethanolamine as monotherapy in patients with pulmonary arterial hypertension [Abstract]","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"961A","DOI":"10.1378\/chest.2256760","article-title":"Individualized dosing of selexipag based on tolerability in the GRIPHON study shows consistent efficacy and safety in patients with pulmonary arterial hypertension (PAH)","volume":"184","author":"Channick","year":"2015","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/j.healun.2015.01.443","article-title":"Effect of selexipag on morbidity\/mortality in pulmonary arterial hypertension: Results of the griphon study","volume":"34","author":"Galie","year":"2015","journal-title":"Journal of Heart and Lung Transplantation"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0018|cit18","first-page":"381","article-title":"Effect of selexipag on long-term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline: Results from the GRIPHON study","volume":"36","author":"Lang","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"A1538","DOI":"10.1016\/S0735-1097(15)61538-8","article-title":"Effect of selexipag on morbidity\/mortality in pulmonary arterial hypertension: Results of the GRIPHON study","volume":"65","author":"McLaughlin","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 59","key":"10.1002\/14651858.CD012785.pub2-BIB0020|cit20","first-page":"OA4995","article-title":"Effect of selexipag on longterm outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results","volume":"46","author":"Sitbon","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"26","key":"10.1002\/14651858.CD012785.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012785.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4187\/respcare.05280","article-title":"Treatment of pulmonary arterial hypertension using initial combination therapy of bosentan and iloprost","volume":"62","author":"Han","year":"2017","journal-title":"Respiratory Care"},{"issue":"4","key":"10.1002\/14651858.CD012785.pub2-BIB0023|cit23","first-page":"160S","article-title":"A randomised, double-blind, placebo-controlled study of iloprost inhalation as add-on therapy to bosentan in pulmonary arterial hypertensions (PAH)","volume":"128","author":"McLaughlin","year":"2005","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012785.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.rmed.2010.01.008","article-title":"Long-term therapy with inhaled iloprost in patients with pulmonary hypertension","volume":"104","author":"Olschewski","year":"2010","journal-title":"Respiratory Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012785.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012785.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0028|cit28","first-page":"A2515","article-title":"Efficacy, safety and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a phase IIa study in pulmonary arterial hypertension (PAH)","volume":"181","author":"Simonneau","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012785.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0030|cit30","unstructured":"Torbicki A Lang I Hoeper M Delcroix M Karlocai K Galie N A new drug class for Pulmonary Arterial Hypertension (PAH): results from a phase II study of ACT 293987, an oral IP receptor agonist European Society of Cardiology Congress; 2010 28 Aug - 1 Sep; Stockholm 2010 22"},{"issue":"55","key":"10.1002\/14651858.CD012785.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"4","author":"McLaughlin","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"3-4","key":"10.1002\/14651858.CD012785.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000367630","article-title":"Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects","volume":"94","author":"Bruderer","year":"2014","journal-title":"Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD012785.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1592\/phco.26.8.1203","article-title":"Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II-IV symptoms","volume":"26","author":"Herald","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"22","key":"10.1002\/14651858.CD012785.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJM199605303342214","article-title":"Intravenous epoprostenol for primary pulmonary hypertension","volume":"334","author":"Higenbottam","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012785.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/hrt.79.2.175","article-title":"Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost","volume":"79","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0037|cit37","first-page":"A6066","article-title":"Addition of beraprost to existing sildenafil therapy in patients with pulmonary arterial hypertension: a randomized, open-label study (Best study)","volume":"187","author":"Jing","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012785.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7326\/0003-4819-133-2-200007180-00016","article-title":"Epoprostenol for pulmonary hypertension in scleroderma","volume":"133","author":"Klings","year":"2000","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0039|cit39","unstructured":"Kumar P Arneson C Laliberte K Nelsen AC Dose-response relationship of oral treprostinil diolamine (TRE) in patients with pulmonary arterial hypertension (PAH) American Thoracic Society International Conference; 2013 May 17-22; Philadelphia 2013 A3271"},{"issue":"9","key":"10.1002\/14651858.CD012785.pub2-BIB0040|cit40","first-page":"1203","article-title":"Clinical trial of long-acting beraprost sodium in Japanese patients with pulmonary arterial hypertension","volume":"34","author":"Kunieda","year":"2013","journal-title":"Therapeutic Research"},{"issue":"4","key":"10.1002\/14651858.CD012785.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7326\/0003-4819-139-4-200308190-00025","article-title":"Treatment of severe pulmonary hypertension with inhaled iloprost","volume":"139","author":"Leuchte","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"21","key":"10.1002\/14651858.CD012785.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1055\/s-2001-14422","article-title":"Therapy of severe pulmonary hypertension with prostacyclin and iloprost","volume":"126","author":"Matthes","year":"2001","journal-title":"Deutsche Medizinische Wochenschrift (1946)"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0043|cit43","unstructured":"NCT00709098 Safety study extension of iloprost power 15 in pulmonary arterial hypertension (PROWESS 15 Ext) clinicaltrials.gov\/ct2\/show\/NCT00709098"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0044|cit44","unstructured":"NCT00709956 Iloprost power 15 in pulmonary arterial hypertension (PROWESS 15) clinicaltrials.gov\/ct2\/show\/NCT00709956"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0045|cit45","unstructured":"NCT00760916 FREEDOM DR: oral treprostinil in combination with an endothelin receptor antagonist (ERA) and\/or a phosphodiesterase-5 (PDE-5) inhibitor or as monotherapy for the treatment of pulmonary arterial hypertension (PAH) clinicaltrials.gov\/ct2\/show\/NCT00760916"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0046|cit46","unstructured":"NCT00993408 Study of ACT-293987 (NS-304) in pulmonary arterial hypertension (PAH) clinicaltrials.gov\/ct2\/show\/NCT00993408"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0047|cit47","unstructured":"NCT01094067 Tezosentan in patients with pulmonary arterial hypertension clinicaltrials.gov\/ct2\/show\/NCT01094067"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0048|cit48","unstructured":"NCT01105091 Epoprostenol for injection in pulmonary arterial hypertension (EPITOME-1) clinicaltrials.gov\/ct2\/show\/NCT01105091"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0049|cit49","unstructured":"NCT01302444 Treprostinil combined with tadalafil for pulmonary hypertension (T2) clinicaltrials.gov\/ct2\/show\/NCT01302444"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0050|cit50","unstructured":"NCT01393795 Qutenza\u00ae-Remodulin\u00ae in pulmonary arterial hypertension patients clinicaltrials.gov\/ct2\/show\/NCT01393795"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0051|cit51","unstructured":"NCT01557647 Safety and efficacy of inhaled treprostinil in patients with PAH clinicaltrials.gov\/ct2\/show\/NCT01557647"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0052|cit52","unstructured":"NCT01598441 Multicenter study of iloprost inhaled in pulmonary hypertension after repair of congenital heart diseases (CHD) clinicaltrials.gov\/ct2\/show\/NCT01598441"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0053|cit53","unstructured":"NCT02032836 Comparative PK PD Study in PAH patients (Fox vs. I-Neb) clinicaltrials.gov\/ct2\/show\/NCT02032836"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0054|cit54","unstructured":"NCT02482402 Iloprost for bridging to heart transplantation in PH (BRIDGE) clinicaltrials.gov\/ct2\/show\/NCT02482402"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0055|cit55","unstructured":"NCT02893995 Safety, tolerability, pharmacokinetics and efficacy of two different rates of subcutaneous remodulin\u00ae dose titration in pulmonary arterial hypertension clinicaltrials.gov\/ct2\/show\/NCT02893995"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0056|cit56","unstructured":"NCT02999906 Study to compare triple therapy (oral treprostinil, ambrisentan, and tadalafil) with dual therapy (ambrisentan, tadalafil, and placebo) in subjects with pulmonary arterial hypertension clinicaltrials.gov\/ct2\/show\/NCT02999906"},{"issue":"1","key":"10.1002\/14651858.CD012785.pub2-BIB0057|cit57","first-page":"3","article-title":"Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension","volume":"52","author":"Olschewski","year":"1998","journal-title":"Pneumologie"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD012785.pub2-BIB0058|cit58","first-page":"395s","article-title":"A comparison of three month's treatment with nebulised iloprost (Ilo) and continuous intravenous prostacyclin (PG1\u00b2) infusion for severe pulmonary hypertension (PH)","volume":"16","author":"Pepke-Zaba","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012785.pub2-BIB0059|cit59","first-page":"A214","article-title":"A comparison of three month's treatment with nebulised iloprost (Ilo) and continuous intravenous prostacyclin (PGI2) infusion for severe pulmonary hypertension (PH)","volume":"161","author":"Pepke-Zaba","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1378\/chest.2276665","article-title":"Riociguat in combination with prostacyclin analogs for the treatment of pulmonary arterial hypertension (PAH): a subgroup analysis of the PATENT studies","volume":"148","author":"Preston","year":"2015","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD012785.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.117.1.14","article-title":"Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus","volume":"117","author":"Robbins","year":"2000","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD012785.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1378\/chest.06-2118","article-title":"Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. [Erratum appears in Chest. 2007 Nov;132(5): 1721]","volume":"132","author":"Rubenfire","year":"2007","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD012785.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1378\/chest.127.5.1870","article-title":"Epoprostenol and nesiritide in pulmonary hypertension","volume":"127","author":"Rubin","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD012785.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1183\/09031936.01.00400101","article-title":"Long-term treatment of pulmonary hypertension with aerosolized iloprost","volume":"18","author":"Saba","year":"2001","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0065|cit65","first-page":"A3281","article-title":"Effect of oral treprostinil on hemodynamics during exercise in patients with pulmonary hypertension","volume":"187","author":"Saggar","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0066|cit66","first-page":"A3382","article-title":"Comparison of acute hemodynamic effects of inhaled nitric oxide (iNo) and inhaled epoprostenol (iEPO) in patients with pulmonary arterial hypertension (PAH) [Abstract]","volume":"181","author":"Shah","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012785.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2006.06.062","article-title":"Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies","volume":"48","author":"Voswinckel","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012785.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-144-2-200601170-00026","article-title":"Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension. [Erratum appears in Ann Intern Med. 2006 Jun 6;144(11):863]","volume":"144","author":"Voswinckel","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012785.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"635b","DOI":"10.1378\/chest.132.4_MeetingAbstracts.635b","article-title":"Intravenous treprostinil in pulmonary arterial hypertension: a controlled trial in India","volume":"132","author":"Wade","year":"2007","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD012785.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/FJC.0b013e31828685da","article-title":"Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension","volume":"61","author":"White","year":"2013","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0071|cit71","first-page":"A3270","article-title":"An open-label extension trial of oral treprostinil in subjects with pulmonary arterial hypertension","volume":"187","author":"White","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD012785.pub2-BIB0072|cit72","first-page":"324s","article-title":"Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension","volume":"18","author":"Wilkens","year":"2001","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD012785.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled Iloprost plus oral sildenafil in patients with primary pulmonary hypertension","volume":"104","author":"Wilkens","year":"2001","journal-title":"Circulation"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD012785.pub2-BIB0074|cit74","first-page":"A3298","article-title":"CONFRONT","volume":"187","author":"Zamanian","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0075|cit75","unstructured":"NCT01908699 Beraprost-314d added-on to Tyvaso\u00ae (BEAT) clinicaltrials.gov\/ct2\/show\/NCT01908699"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0076|cit76","unstructured":"NCT02558231 The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension clinicaltrials.gov\/ct2\/show\/NCT02558231"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0077|cit77","first-page":"A5680","article-title":"Rationale and design of trace: a double-blind, placebo-controlled phase 4 study in pulmonary arterial hypertension to assess the effect of selexipag on physical activity, patient-reported symptoms and their impact, in daily life","volume":"197","author":"Preston","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012785.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","article-title":"Diagnosis and assessment of pulmonary arterial hypertension","volume":"54","author":"Badesch","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012785.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1183\/09031936.06.00130405","article-title":"Measurement of quality of life in pulmonary hypertension and its significance","volume":"28","author":"Cenedese","year":"2006","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012785.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"343-9","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension: results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012785.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/jcpt.12170","article-title":"Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil inpatients with pulmonary arterial hypertension: a retrospective case series","volume":"39","author":"Enderby","year":"2014","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD012785.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.recesp.2016.01.002","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"69","author":"Gali\u00e8","year":"2016","journal-title":"Revista Espanola de Cardiologia"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0084|cit84","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02602348","article-title":"Development and testing of a new measure of health status for clinical trials in heart failure","volume":"4","author":"Guyatt","year":"1989","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0086|cit86","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"9","key":"10.1002\/14651858.CD012785.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012785.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/thoraxjnl-2015-207170","article-title":"The molecular targets of approved treatments for pulmonary arterial hypertension","volume":"71","author":"Humbert","year":"2015","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD012785.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"342-9","DOI":"10.1086\/529552","article-title":"Bloodstream infections in patients given treatment with intravenous prostanoids","volume":"29","author":"Kallen","year":"2008","journal-title":"Infection Control and Hospital Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD012785.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1513\/AnnalsATS.201512-824OC","article-title":"The minimal important difference in Borg dyspnea score in pulmonary arterial hypertension","volume":"13","author":"Khair","year":"2016","journal-title":"Annals of the American Thoracic Society"},{"issue":"8","key":"10.1002\/14651858.CD012785.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11136-005-3513-4","article-title":"The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension","volume":"15","author":"McKenna","year":"2006","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1477-82","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD012785.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003495-200262010-00005","article-title":"Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension","volume":"62","author":"Melian","year":"2002","journal-title":"Drugs"},{"issue":"4","key":"10.1002\/14651858.CD012785.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5339\/gcsp.2014.53","article-title":"Role of prostacyclin in pulmonary hypertension","volume":"2014","author":"Mitchell","year":"2014","journal-title":"Global Cardiology Science and Practice"},{"issue":"7","key":"10.1002\/14651858.CD012785.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"issue":"15","key":"10.1002\/14651858.CD012785.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2146\/ajhp160798","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"74","author":"Noel","year":"2017","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"1","key":"10.1002\/14651858.CD012785.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0099|cit99","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"25","key":"10.1002\/14651858.CD012785.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"780-8","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0102|cit102","first-page":"A2500","article-title":"EPITOME-2, An open-label study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from Flolan","volume":"185","author":"Sitbon","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012785.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"160055","DOI":"10.1183\/16000617.0055-2016","article-title":"Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience","volume":"26","author":"Sitbon","year":"2017","journal-title":"European Respiratory Review"},{"issue":"3","key":"10.1002\/14651858.CD012785.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/112972980600700304","article-title":"Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension","volume":"7","author":"Tapson","year":"2006","journal-title":"Journal of Vascular Access"},{"issue":"6","key":"10.1002\/14651858.CD012785.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1103-10","DOI":"10.1183\/09031936.00042107","article-title":"A USA-based registry for pulmonary arterial hypertension: 1982-2006","volume":"30","author":"Thenappan","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012785.pub2-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002994.pub2","article-title":"Prostacyclin for pulmonary hypertension in adults","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012785.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T16:18:07Z","timestamp":1673021887000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012785.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":106,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012785.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}